Moderna is suing Pfizer-BioNTech for vaccine patent infringement; the White House is pushing for American citizens to have access to all publicly funded research by 2026; Monkeypox cases drop 21% globally, stopping a months-long increase.
Moderna alleges that Pfizer-BioNTech improperly used the company’s foundational technology to develop its COVID-19 vaccine, according to a lawsuit filed on Friday in the United States and Germany. The legal battle will likely take 3 to 5 years, as most patent lawsuits end up in appeals courts. Pfizer had not received the lawsuit at time of questioning but defended its vaccine in a similar lawsuit from CureVac, a German company that attempted to make its own COVID-19 vaccine. Pfizer said its work was original and that they would defend against any lawsuit.
The White House has announced it is pushing for all publicly funded research to be accessible to the public, stating that all academic journals will have to provide immediate access to any such papers. This would end a policy that could allow publishers to keep such research behind a paywall for up to 1 year. The policy will be fully implemented in early 2026. Supporters state this could be beneficial for students at universities who cannot afford to pay for subscriptions for academic papers. It could also keep the public in the loop on groundbreaking research, such as cancer breakthroughs or clean-energy technology.
The World Health Organization (WHO) has announced that monkeypox cases have dropped 21% in the past week, which may indicate the slowing spread in Europe. Since April, there have been 45,000 cases of monkeypox reported in 98 countries, with 60% of cases in the Americas. Although the decrease is a good sign for Europe, the WHO says that the Americas continue to see a steep rise in case numbers, with Latin America struggling due to lack of awareness and public health measures. Last week, British health authorities said there were signs of a slowing spread; they downgraded the country’s monkeypox outbreak last month due to evidence of the disease only spreading among men who were gay, bisexual, or had sex with other men.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More